Andrew Muinonen‐Martin

Author

Also Known As

A. Muinonen-Martin, A. Muinonen‐Martin, Andrew J Muinonen-Martin, Andrew J. Muinonen-Martin, Andrew James Muinonen-Martin, Andrew Muinonen-Martin, Andrew Muinonen‐Martin, Andrew J Muinonen-Martin

Publications

434

Citations

H-Index

Concepts

All Affiliations

Cancer Research UK Scotland Institute Leeds Teaching Hospitals NHS Trust York Teaching Hospital NHS Foundation Trust University of Connecticut

About

Andrew Muinonen‐Martin is an author at Cancer Research UK Scotland Institute specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	167
2	Engineering	1	1	119
3	Health Sciences	1	1	11
4	Biomedical Engineering	1	1	119
5	Cell Biology	1	1	119

Andrew Muinonen‐Martin

Publications

405

Citations

H-Index

Page 1

	Year	Citations
Melanoma Cells Break Down LPA to Establish Local Gradients That Drive Chemotactic Dispersal Andrew Muinonen‐Martin, Olivia Susanto, Elizabeth A. Smethurst, PLoS Biology	2014	131
An Improved Chamber for Direct Visualisation of Chemotaxis Andrew Muinonen‐Martin, Douwe M. Veltman, Gabriela Kalna, PLoS ONE EngineeringMicroscopyPolynomial GradientsBiomedical EngineeringTissue Imaging	2010	119
LPP3 mediates self-generation of chemotactic LPA gradients by melanoma cells Olivia Susanto, Yvette W. H. Koh, Nick Morrice, Journal of Cell Science	2017	54
Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells E. Natafji, Cunjing Yu, Sharizan Abdul-Ghaffar, Journal of Allergy and Clinical Immunology	2016	41
Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases Elizabeth Blakeway, Noha Elshimy, Andrew Muinonen‐Martin, Melanoma Research Checkpoint Blockade ImmunotherapyImmunologyPathologyPembrolizumab TherapyDermatology	2019	37
Measuring Chemotaxis Using Direct Visualization Microscope Chambers Andrew Muinonen‐Martin, David A. Knecht, Douwe M. Veltman, Methods in molecular biology	2013	12
DETECTION phase II/III trial: Circulating tumor DNA–guided therapy for stage IIB/C melanoma after surgical resection. Rebecca Lee, Dominic G. Rothwell, Richard A. Jackson, Journal of Clinical Oncology Surgical OncologyImmunologyImmunoeditingPathologyStage Iib/c Melanoma	2022	11

Page 1